Alkermes plc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (41)

Latest Posts

About This Stock More About This Stock
Alkermes: Progress In Antipsychotics
Article By: MoneyShow.com
Saturday, October 17, 2020 6:16 PM EDT
Alkermes has the potential to generate solid sales based on its ability to alleviate serious mental illness while safety mitigating weight gain that is common in antipsychotics.
In this article: ALKS
Read
Alkermes Upgraded To Buy From Neutral At Mizuho
Article By: The Fly
Thursday, October 15, 2020 7:57 AM EDT
Mizuho analyst Vamil Divan upgraded Alkermes to Buy from Neutral with a price target of $24, up from $19.
In this article: ALKS
Read
Alkermes Comments On FDA Panel May Pressure Shares, Says Mizuho
Article By: The Fly
Friday, August 21, 2020 11:16 AM EDT
Analyst Vamil Divan believes details in Alkermes' announcement this morning that the FDA will hold an advisory committee meeting on October 9 to discuss ALKS 3831, a treatment of schizophrenia and bipolar disorder, may put pressure on the shares.
In this article: ALKS
Read
Alkermes Downgraded To Sell From Neutral At Goldman Sachs
Article By: The Fly
Thursday, July 30, 2020 6:05 AM EDT
Goldman Sachs analyst Terence Flynn downgraded Alkermes to Sell from Neutral with a price target of $15, down from $19.
In this article: ALKS
Read
Alkermes Targets Bipolar Disorder And Schizophrenia
Article By: MoneyShow.com
Sunday, February 16, 2020 11:52 AM EDT
We strongly recommend that investors take advantage of the weakness and buy Alkermes, whose treatment of schizophrenia and bipolar disorder has been accepted by the FDA for review.
In this article: ALKS Also: BIIB, MYL
Read

PARTNER HEADLINES

Latest Tweets for $ALKS

No tweets yet!